{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:05:45Z","timestamp":1785240345187,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:00:30Z","timestamp":1776283230000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCR-ABL1 Transcript \u226410% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Eman O.","family":"Rasekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna M.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ghareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-684X","authenticated-orcid":false,"given":"Sally","family":"Elfishawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9976","key":"10.1016\/j.clml.2026.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"suppl 2","key":"10.1016\/j.clml.2026.04.007_bib0002","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2026.04.007_bib0003","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1007\/s00277-015-2323-1","article-title":"Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients","volume":"94","author":"Hochhaus","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171041","article-title":"Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia","volume":"12","author":"El Missiry","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.clml.2026.04.007_bib0005","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMc2518028","article-title":"Treatment-free remission in chronic myeloid leukemia in low- and middle-income countries","volume":"394","author":"Annamalay","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.04.007_bib0006","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/MS9.0000000000003069","article-title":"A new chapter in CML treatment: the promise of asciminib","volume":"87","author":"Akhtar","year":"2025","journal-title":"Ann Med Surg"},{"issue":"10","key":"10.1016\/j.clml.2026.04.007_bib0007","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"5.5","key":"10.1016\/j.clml.2026.04.007_bib0008","first-page":"611","article-title":"NCCN Guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia","volume":"17","author":"Shah","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"4","key":"10.1016\/j.clml.2026.04.007_bib0009","article-title":"Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic imatinib-induced liver injury","volume":"11","author":"Lopina","year":"2019","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.clml.2026.04.007_bib0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.04.007_bib0011","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.007_bib0012","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.16506","article-title":"Prospects for achieving treatment-free remission in chronic myeloid leukaemia","volume":"190","author":"Saglio","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.007_bib0014","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2026.04.007_bib0015","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2026.04.007_bib0016","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.007_bib0017","unstructured":"Chronic myeloid leukemia: pathogenesis, clinical manifestations, and diagnosis\u2014UpToDate. Available from: https:\/\/www.uptodate.com\/contents\/chronic-myeloid-leukemia-pathogenesis-clinical-manifestations-and-diagnosis?source=history."},{"key":"10.1016\/j.clml.2026.04.007_bib0018","unstructured":"Gleevec (imatinib mesylate) FDA approval history\u2014drugs.Com. Available from: https:\/\/www.drugs.com\/history\/gleevec.html."},{"issue":"13","key":"10.1016\/j.clml.2026.04.007_bib0019","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2025029210","article-title":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial","volume":"147","author":"Cortes","year":"2026","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473082","article-title":"Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia?","volume":"45","author":"Shanmuganathan","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"23","key":"10.1016\/j.clml.2026.04.007_bib0021","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.04.007_bib0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","article-title":"The role of early molecular response in the management of chronic phase CML","volume":"12","author":"Harrington","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.clml.2026.04.007_bib0023","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3390\/ijms20092226","article-title":"Clinical implications of discordant early molecular responses in CML patients treated with Imatinib","volume":"20","author":"Stella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2026.04.007_bib0024","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3332\/ecancer.2020.1089","article-title":"Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with imatinib and barriers to access treatment","volume":"14","author":"Henke","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"10.1016\/j.clml.2026.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00277-023-05189-3","article-title":"Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response","volume":"102","author":"Ferreira","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4576455","article-title":"Early molecular response to Imatinib first-line therapy and predictive factors of poor outcomes for chronic myeloid leukemia patients in C\u00f4te d\u2019Ivoire","volume":"2024","author":"Koffi","year":"2024","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2026.04.007_bib0027","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.clml.2015.03.014","article-title":"Factors affecting early molecular response in chronic myeloid leukemia","volume":"15","author":"Chikkodi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.04.007_bib0028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12288-019-01143-4","article-title":"CML in elderly: does age matter?","volume":"36","author":"Lokesh","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"10.1016\/j.clml.2026.04.007_bib0029","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.007_bib0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2026.04.007_bib0031","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-the Surveillance, Epidemiology, and End Results database, 2000-2019","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.04.007_bib0032","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1182\/blood-2022-163080","article-title":"Five-year overall survival analysis using first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase in a prospective observational study (SIMPLICITY)","volume":"140","author":"Mauro","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.04.007_bib0033","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"S1","key":"10.1016\/j.clml.2026.04.007_bib0034","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5045\/br.2023.2023035","article-title":"Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia","volume":"58","author":"Han","year":"2023","journal-title":"Blood Res"},{"key":"10.1016\/j.clml.2026.04.007_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1393191","article-title":"Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study","volume":"14","author":"Murbach","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.007_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.928136","article-title":"Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia","volume":"10","author":"Kim","year":"2022","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.clml.2026.04.007_bib0037","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/cam4.5158","article-title":"BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: a study from the \u201cGRUPPO TRIVENETO LMC\u201d","volume":"12","author":"Di Giusto","year":"2023","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.04.007_bib0038","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2018-99-114036","article-title":"B3a2 Transcript is an independent factor for the achievement of a deep molecular response in chronic phase\u2014chronic myeloid leukemia patients treated with Imatinib in first-line","volume":"132","author":"Da Silva","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.007_bib0039","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/0022-3859.68640","article-title":"Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?","volume":"56","author":"Malhotra","year":"2010","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.clml.2026.04.007_bib0040","article-title":"Chronic-phase chronic myeloid leukemia: incidence of BCR\/ABL transcript and its correlation with presenting features, response to treatment, and survival","volume":"20","author":"Laabidi","year":"2023","journal-title":"Leuk Res Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:56:58Z","timestamp":1785239818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001072"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL1 Transcript \u226410% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}